Combining Ginkgo Leaf Pills and Huperzine A with Nerve Stimulation for Cognitive Impairment After Brain Injury
Official title: The Study of Ginkgo Leaf Dropping Pills and Huperzine A Injection Combined With Median Nerve Electrical Stimulation in the Treatment of Cognitive Impairment After Brain Injury
Run by Wanbangde Pharmaceutical Group Co., LTD · NCT06704334 · Data updated 2026-11-12
This study is testing if a mix of ginkgo leaf pills, huperzine A injections, and nerve stimulation can help people with memory and thinking problems after a brain injury.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Wanbangde Pharmaceutical Group Co., LTD Industry-sponsored |
| Locations | 1 site (Ganzhou, Jiangxi) |
| Status | Recruiting |
| Started | April 1, 2024 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | August 17, 2026 |
| Trial ID | NCT06704334 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 years old with cognitive impairment resulting from brain injury.
✕Probably not a fit
Patients with severe underlying diseases, consciousness disorders, or contraindications to the treatments may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to evaluate the effectiveness of a combination treatment involving ginkgo biloba dropping pills, huperzine A injection, and median nerve electrical stimulation in patients suffering from cognitive impairment following brain injury. The study is designed as a randomized, controlled, single-center exploratory trial, focusing on the neuroprotective effects and potential improvements in cognitive function. Participants will be monitored for changes in their cognitive abilities as a result of the interventions.
Why it matters
Potential benefit: If successful, this treatment could significantly enhance cognitive recovery in patients with brain injury.
How similar studies have gone: While this approach combines established treatments, the specific combination and its effects on cognitive impairment after brain injury are relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Be over 18 years old * Residual cognitive impairment due to brain injury * No previous history of brain-related diseases except this one Exclusion Criteria: * The patient had severe underlying disease and unstable vital signs * The patient was complicated with consciousness disorder and could not cooperate with cognitive function assessment * Allergic to drugs or contraindications in drug use * There are contraindications of median nerve electrical stimulation
Where it's running
-
The Ganzhou City People's Hospital
Ganzhou, Jiangxi, China Recruiting
Study contacts
- Study coordinator: Dong Wang
- Email: 2623693068@qq.com
- Phone: 18007076858
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.